Paroxetine HCI CAS: 78246-49-8

Name: Paroxetine Hydrochloride
Synonyms:(3s,4r)-orid;(3s-trans)-id;3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-,hydrochloride,(3s-trans)-piperidin;3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidinhydrochl;3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidinhydrochlor
CAS:78246-49-8
MF:C19H21ClFNO3
MW:365.83
Melting point :129-131°C
Chemical Properties:White Crystalline Powder
Usage:Paroxetine is an antidepressant drug of the SSRI type, A selective serotonin reuptake inhibitor. Used as an antidepressant.
Grade: USP standard
Hot Raw Powder Paroxetine Hydrochloride / Paroxetine for Antidepressant

 

Paroxetine Hydrochloride Medical Uses: 

Paroxetine is primarily used to treat major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, panic disorder, generalized anxiety disorder, premenstrual dysphoric disorder and menopausal hot flashes.

Depression

A variety of meta analyses have been conducted to evaluate the efficacy of paroxetine in depression. They have variously concluded that paroxetine is superior or equivalent to placebo and that it is equivalent or inferior to other antidepressants. Despite this, there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point.

Obsessive-compulsive disorder

Paroxetine is used in the treatment of obsessive-compulsive disorder. Comparative efficacy of paroxetine is equivalent to that of clomipramine and venlafaxine. Paroxetine is also effective for children with obsessive-compulsive disorder.

Panic disorder
Paroxetine was the first antidepressant formally approved in the United States for the treatment of panic disorder. Several studies have concluded that paroxetine is superior to placebo in the treatment of panic disorder.

Social anxiety disorder

Paroxetine has demonstrated efficacy for the treatment of social anxiety in adults and children. There was a significant improvement in scores on the Liebowitz Social Anxiety Scale and Social Phobia Inventory compared with placebo. It is also beneficial for people with co-occurring social anxiety disorder and alcohol use disorder.

Menopausal hot flashes

On June 28, 2013 U.S. FDA approved low dose paroxetine for the treatment of moderate-to-severe vasomotor symptoms (e.g. hot flashes and night sweats) associated with menopause. Randomized controlled trials have shown modest relief in such cases[citation needed]. At the low dose used for menopausal hot flashes side effects are similar to placebo and dose tapering is not required for discontinuation.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s